Stephen Toovey
Directeur/Bestuurslid bij 60 DEGREES PHARMACEUTICALS, INC.
Vermogen: 4 088 $ op 31-05-2024
Profiel
Stephen Toovey is the founder of Shanghai Ark Biopharmaceutical Co., Ltd.
(founded in 2014).
He is currently working as an Independent Director at 60 Degrees Pharmaceuticals, Inc. since 2023.
Dr. Toovey obtained a doctorate degree from Ghent University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 17-05-2024 | 14 000 ( 0.12% ) | 4 088 $ | 31-05-2024 |
Actieve functies van Stephen Toovey
| Bedrijven | Functie | Begin |
|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 12-07-2023 |
Eerdere bekende functies van Stephen Toovey
| Bedrijven | Functie | Einde |
|---|---|---|
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Oprichter | 01-01-2020 |
Opleiding van Stephen Toovey
| Ghent University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
| 60 Degrees Pharmaceuticals, Inc. | |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Health Technology |
